storage stability raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-25 and is reviewed periodically as new material appears.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
SR9009 is frequently discussed in fitness and research-chemical contexts, yet it has no approved medical indication. Regulatory agencies have not authorized it for human use, and it is not a standard prescription drug. Some sports organizations list it as a prohibited substance because of its potential performance-enhancing properties. Published human data are sparse, so claims about its effects in people often rely on animal models or anecdotal reports. Quality and identity of online materials can vary widely.
SR9009 is a synthetic small molecule studied as a REV-ERB agonist. REV-ERBα and REV-ERBβ are nuclear receptors that help regulate circadian rhythms and metabolic gene expression. The compound was identified in academic screening efforts to find synthetic ligands for these receptors. In cell and animal studies, SR9009 alters transcription of genes involved in lipid and glucose metabolism, and it can shift circadian behavior. It is not an approved therapeutic agent.
Mechanistically, SR9009 binds the ligand-binding domain of REV-ERBα/β and enhances recruitment of corepressor complexes. This represses target genes rather than activating them. Because REV-ERB proteins normally compete with ROR proteins at shared response elements, the net effect depends on tissue and timing. Researchers use SR9009 to probe how nuclear receptor signaling links the clock to metabolism, inflammation, and muscle biology. Findings are largely preclinical, and the precise contribution of each receptor subtype remains under study.
The risk of experiencing severe withdrawal symptoms is high if a patient has become physically or mentally dependent and discontinues tapentadol abruptly. These symptoms can range from mild discomfort to more serious health issues, making abrupt cessation dangerous. When a person has been using tapentadol regularly for an extended period of time, tapering off the drug gradually is generally recommended. This approach allows the body to adjust to lower doses over time, minimizing the risk of withdrawal symptoms and ensuring a safer transition away from tapentadol. Gradual withdrawal helps to avoid the shock to the system that comes with abrupt discontinuation, ultimately making the process more manageable for a person who has developed a dependence. The symptoms of tapentadol withdrawal are typical of other opioids and can include anxiety, restlessness, fever or chills, joint pain, nausea or vomiting, loss of appetite, runny nose, stomach cramps, sweating, tremor, or insomnia. However, tapentadol withdrawal symptoms may be more intense and prolonged when compared with more typical opioids such as codeine or oxycodone, in some respects, due to the fact that tapentadol acts also as norepinephrine reuptake inhibitor (NRI). People withdrawing from a tapentadol dependency may experience both typical opioid withdrawal symptoms, such as fever or nausea, along with symptoms associated more commonly with the discontinuation of drugs which block the reuptake of norepinephrine.
=== Doping in sport === Selegline is on the World Anti-Doping Agency (WADA)'s list of prohibited substances. It is classified as a "stimulant" in this list, along with various amphetamines, methylphenidate, adrenergic sympathomimetics, modafinil, and other agents. A review of the pharmacology of WADA prohibited substances noted that although selegiline is classified as a stimulant in the WADA prohibited substances list and stimulants can enhance physical performance, selegiline was seemingly included in the list not because of any short-term stimulant effects of its own, but rather because it metabolizes into small amounts of levomethamphetamine and levoamphetamine and can produce false positives for amphetamines on drug tests. In any case, levomethamphetamine and levoamphetamine are catecholamine releasing agents and can produce sympathomimetic and psychostimulant effects with sufficiently high exposure. Such actions may have performance-enhancing effects.
== Mechanism of action == Ro65-6570 is an opioid drug, it works by activating opioid receptors. However, instead of acting at the mu, kappa and delta receptors, it is instead an agonist at the nociceptin receptor.
== Brain and nervous system == Astrocytoma Anaplastic astrocytoma Brainstem glioma Choroid plexus carcinoma Craniopharyngioma Ependymoma Ganglioneuroma Glioblastoma Glioma Hemangioblastoma Medulloblastoma Meningioma Neuroblastoma Neurofibroma Oligodendroglioma Paraganglioma Pineal astrocytoma Pineocytoma Pineoblastoma Pituitary adenoma Pilocytic astrocytoma Primary central nervous system lymphoma Primitive neuroectodermal tumor Schwannoma Visual pathway and hypothalamic glioma
Sources: en.wikipedia.org
When a sequence motif appears in the exon of a gene, it may encode the "structural motif" of a protein; that is a stereotypical element of the overall structure of the protein. Nevertheless, motifs need not be associated with a distinctive secondary structure. "Noncoding" sequences are not translated into proteins, and nucleic acids with such motifs need not deviate from the typical shape (e.g. the "B-form" DNA double helix). Outside of gene exons, there exist regulatory sequence motifs and motifs within the "junk", such as satellite DNA. Some of these are believed to affect the shape of nucleic acids (see for example RNA self-splicing), but this is only sometimes the case. For example, many DNA binding proteins that have affinity for specific DNA binding sites bind DNA in only its double-helical form. They are able to recognize motifs through contact with the double helix's major or minor groove. Short coding motifs, which appear to lack secondary structure, include those that label proteins for delivery to particular parts of a cell, or mark them for phosphorylation. Within a sequence or database of sequences, researchers search and find motifs using computer-based techniques of sequence analysis, such as BLAST. Such techniques belong to the discipline of bioinformatics. See also consensus sequence.
By taking command in person, Buller had allowed the overall direction of the war to drift. Because of concerns about his performance and negative reports from the field, he was replaced as Commander in Chief by Lord Roberts. Roberts assembled a new team for headquarters staff from far and wide: Lord Kitchener (Chief of Staff) from the Sudan; Frederick Russell Burnham (Chief of Scouts), the American scout, from the Klondike; George Henderson from the Staff College; Neville Bowles Chamberlain from Afghanistan; and William Nicholson (Military Secretary) from Calcutta. Like Buller, Roberts first intended to attack directly along the Cape Town–Pretoria railway but, again like Buller, was forced to relieve the beleaguered garrisons. Leaving Buller in command in Natal, Roberts massed his main force near the Orange River and along the Western Railway behind Methuen's force at the Modder River and prepared to make a wide outflanking move to relieve Kimberley. Except in Natal, the war had stagnated. Other than a single attempt to storm Ladysmith, the Boers made no attempt to capture the besieged towns. In the Cape Midlands, the Boers did not exploit the British defeat at Stormberg and were prevented from capturing the railway junction at Colesberg. In the dry summer, the grazing on the veld became parched, weakening the Boers' horses and draught oxen, and many Boer families joined their menfolk in the siege lines and laagers (encampments), fatally encumbering Cronjé's army.
An mRNA vaccine (or RNA vaccine) is a novel type of vaccine which is composed of the nucleic acid RNA, packaged within a vector such as lipid nanoparticles. Among the COVID-19 vaccines are a number of RNA vaccines to combat the COVID-19 pandemic and some have been approved or have received emergency use authorization in some countries. For example, the Pfizer-BioNTech vaccine and Moderna mRNA vaccine are approved for use in adults and children in the US.
Sources: en.wikipedia.org
1993/1250) Aviation Security (Jersey) Order 1993 (S.I. 1993/1251) Financial Provisions (Northern Ireland) Order 1993 (S.I. 1993/1252) Serbia and Montenegro (United Nations Sanctions) (Channel Islands) Order 1993 (S.I. 1993/1253) Serbia and Montenegro (United Nations Sanctions) (Isle of Man) Order 1993 (S.I. 1993/1254) Maximum Number of Judges (No. 2) Order 1993 (S.I. 1993/1255) Arbitration (Foreign Awards) Order 1993 (S.I. 1993/1256) Designs (Convention Countries) Order 1993 (S.I. 1993/1257) Patents and Marks (Convention and Relevant Countries) Order 1993 S.I. 1993/1258) Hackney and Tower Hamlets (London Borough Boundaries) Order 1993 (S.I. 1993/1260) Bromley and Lewisham (London Borough Boundaries) Order 1993 (S.I. 1993/1261) Kensington and Chelsea and Westminster (London Borough Boundaries) Order 1993 (S.I. 1993/1262) Food Premises (Registration) (Welsh Form of Application) Regulations 1993 (S.I. 1993/1270) Greenwich and Lewisham (London Borough Boundaries) Order 1993 (S.I. 1993/1276) Ealing, Hillingdon and Hounslow (London Borough Boundaries) Order 1993 (S.I. 1993/1277) Treatment of Spruce Bark Order 1993 (S.I. 1993/1282) Plant Health (Forestry) (Great Britain) Order 1993 (S.I. 1993/1283) Prohibition of the Keeping or the Release of Live Fish (Pikeperch) (Scotland) Order 1993 (S.I. 1993/1288) A27 Trunk Road (Patching Junction Improvement) Order 1993 (S.I. 1993/1293) A27 Trunk Road (Patching Junction Improvement Slip Roads) Order 1993 (S.I. 1993/1294) A27 Trunk Road (Patching Junction Improvement) (Detrunking) Order 1993 (S.I. 1993/1295)
=== World War I and the American dye industry 1913 – 1930 === Through 1914, the US dye market was dominated by German imports, there were only a few small companies and German subsidiaries. With World War I, however, German dye factories now had to switch to making explosives and German shipping was cut off by British blockades. Prices quickly went up and U. S. companies built plants to meet demand. American pharmaceutical giants, even at that time, like Dow, DuPont, and others began to produce dyes and were extremely successful with simple sulphur and vat dyes. Dow Chemical developed a synthetic process for indigo in 1915, and American industry and universities worked together to reverse engineer German chemical production secrets. After the war some American munitions factories converted to dye-works, intuiting that if the reverse was possible for the German chemical industry during the war, then it ought to be feasible.
==== Post-war German culture ==== At the same time Adorno struck up relationships with contemporary German-language poets such as Paul Celan and Ingeborg Bachmann. Adorno's 1949 dictum—" To write poetry after Auschwitz is barbaric"—posed the question of what German culture could mean after Auschwitz; his own continual revision of this dictum—in Negative Dialectics, for example, he wrote that "Perennial suffering has as much right to expression as a tortured man has to scream"; while in "Commitment," he wrote in 1962 that the dictum "expresses in negative form the impulse which inspires committed literature"—was part of post-war Germany's struggle with history and culture. Adorno additionally befriended the writer and poet Hans Magnus Enzensberger as well as the film-maker Alexander Kluge. In 1963, Adorno was elected to the post of chairman of the German Sociological Society, where he presided over two important conferences: in 1964, on "Max Weber and Sociology" and in 1968, on "Late Capitalism or Industrial Society." A debate launched in 1961 by Adorno and Karl Popper, later published as the Positivist Dispute in German Sociology, arose out of disagreements at the 1959 14th German Sociology Conference in Berlin. Adorno's critique of the dominant climate of post-war Germany was also directed against the pathos that had grown up around Heideggerianism, as practiced by writers like Karl Jaspers and Otto Friedrich Bollnow, and which had subsequently seeped into public discourse.
In this process, the superoxide anion is produced as a by-product of several steps in the electron transport chain. Particularly important is the reduction of coenzyme Q in complex III, since a highly reactive free radical is formed as an intermediate (Q·−). This unstable intermediate can lead to electron "leakage", when electrons jump directly to oxygen and form the superoxide anion, instead of moving through the normal series of well-controlled reactions of the electron transport chain. Peroxide is also produced from the oxidation of reduced flavoproteins, such as complex I. However, although these enzymes can produce oxidants, the relative importance of the electron transfer chain to other processes that generate peroxide is unclear. In plants, algae, and cyanobacteria, ROS are also produced during photosynthesis, particularly under conditions of high light intensity. This effect is partly offset by the involvement of carotenoids in photoinhibition, and in algae and cyanobacteria, by large amounts of iodide and selenium, which involves these antioxidants reacting with over-reduced forms of the photosynthetic reaction centres to prevent the production of ROS.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.